Status:
TERMINATED
Study to Evaluate Efficacy, Safety, Tolerability and Pharmacokinetics of AZD1386 in Patients With Peripheral Neuropathic Pain
Lead Sponsor:
AstraZeneca
Conditions:
Pain
Neuropathic Pain
Eligibility:
All Genders
18-80 years
Phase:
PHASE2
Brief Summary
The primary aim of this study is to investigate if AZD1386 is efficacious as an analgesic in patients with peripheral neuropathic pain. This will be done by comparing the effect of AZD1386 to placebo ...
Eligibility Criteria
Inclusion
- Patients with painful symptoms due to neuropathic pain
- Provision of signed informed consent
- Non pregnant females
Exclusion
- Other pain conditions that may confound assessment of neuropathic pain, as judged by the investigator
- History, and/or presence of somatic disease, which may interfere with the objectives of the study as judged by the investigator
Key Trial Info
Start Date :
September 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
February 1 2010
Estimated Enrollment :
90 Patients enrolled
Trial Details
Trial ID
NCT00976534
Start Date
September 1 2009
End Date
February 1 2010
Last Update
December 23 2009
Active Locations (12)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Calgary, Alberta, Canada
2
Research Site
Halifax, Nova Scotia, Canada
3
Research Site
Toronto, Ontario, Canada
4
Research Site
Aalborg, Denmark